Stem cell biotech Neuroplast enrolls first patient in Phase II clinical trial of transformative Neuro-Cells® treatment for Traumatic Spinal Cord Injury

Neuro-Cells® treatment aims to reduce irreversible damage to the central nervous system from secondary inflammation following trauma The randomized,...

Related Keywords

United States ,Denmark ,Netherlands ,Spain ,Geleen ,Limburg ,Amsterdam ,Noord Holland ,Spanish ,Danish ,Dutch ,Agencia Espa ,Erik Wolters ,Prnewswire Neuroplast ,Antonio Oliviero ,Medicamentosy Productos Sanitarios ,Brightlands Agrifood Fund ,National Videnskabsetisk Komit ,Netherlands Enterprise Agency ,Danish Medicines Agency ,Dutch Ministry Of Economic Affairs ,Traumatic Spinal Cord Injury ,Traumatic Brain Injury ,Frontotemporal Dementia ,Hospital Nacional De Parapl ,Principal Investigators Antonio Oliviero ,Hospital Parapl ,Principal Investigator ,Spinal Cord Injury ,Spinal Cord ,Productos Sanitarios ,Danish Medicines ,Johannes De Munter ,Lumana Invest ,Brightlands Venture Partners ,Netherlands Enterprise ,Brightlands Chemelot Campus ,Hospital De Parapl ,Nacional De Parapl ,Venture Partners ,Chemelot Ventures ,Dutch Ministry ,Economic Affairs ,Spring Lifesciences Communication ,Neuroplast ,